FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
IPO Status: Listed [27th Jul 2021 to 29th Jul 2021]
Glenmark Lifesciences Limited, a leading Active Pharmaceutical Ingredients (API) manufacturer IPO of ₹ 1513.60 Cr opens on 27 July and closes on 29 July. The face value per share is Rs. 2, and the price band is fixed at Rs. 695-720. The floor price is 347.50 times and cap price is 360 times the face value. The lot size of the IPO is 20 shares. Stay tuned with us to know the opening and closing dates, price band, IPO lot size, and more.
IPO Issue Opening Date: | 27th Jul 2021 |
IPO Issue Closing Date: | 29th Jul 2021 |
IPO Issue Price: | ₹695-720 Per Share |
DRHP: | Download DRHP |
RHP: | Download RHP |
Anchor List: | Download Anchor List |
IPO Listing At: | BSE, NSE |
Retail Quota: | 50.23 |
IPO Issue Type: | Book Build Issue |
IPO Issue Size: | ₹1513.60 Cr |
Offer for Sale: | ₹453.60 Cr |
Fresh Issue: | ₹1060 Cr. |
Face Value: | ₹2 Per Equity Share |
IPO Discount: | NA |
Promoter Holding Pre IPO: | 100% |
Promoter Holding Post IPO: | 82.84% |
Allotment Status: | Allotment Status |
BSE Code: | 543322 |
NSE Code: | GLS |
Get important updates regarding Glenmark Life Sciences IPO tentative timeline covering IPO opening, closing, allotment, and listing dates. Dates are updated as they are announced.
IPO Activity | Date |
---|---|
Basis of Allotment Date* | 3rd Aug 2021 |
Refunds Initiation* | 4th Aug 2021 |
Credit of Shares to Demat* | 5th Aug 2021 |
IPO Listing Date* | 6th Aug 2021 |
* - Tentative Dates
IPO Activity | Date |
---|---|
Issue Price | ₹695-720 |
Market Lot: | 20 Shares |
1 Lot Amount: | ₹14400 |
Min Small HNI Lots(2-10 Lakh): | 280 shares(14 lots) |
Min Big HNI Lots(10+ Lakh): |
GMP Date | IPO Price | GMP | Sub2 Sauda Rate | Expected Listing Gain | Last Updated |
---|---|---|---|---|---|
06-08-2021 | 720 | 82 | -- | ₹802 (11.39%) | 6-Aug-2021 10:35 |
**The GMP prices shown here are only news related to the grey market. We do not trade/deal in grey market or subject to rates (sub2), nor do we recommend trading in grey market.
Glenmark Life Sciences Limited has established strong footprint in Active Pharmaceutical Ingredients manufacturing. The company manufactures high-quality APIS for different diseases like cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders, anti-infectives, and others. It operates in business verticals; Generic APIs (Generic and Complex) and CDMO (Contract Development and Manufacturing operations) to serve specialty pharmaceutical companies.
Glenmark sells its products in India as well as other countries like Europe, Japan, Latin America, North America, etc. It has 4 manufacturing plants; 2 are in Gujarat and 2 are in Maharashtra. As of December 31, 2020, the manufacturing facilities have an aggregate installed capacity of 728.8 KL.
Incorporation | Sector | IPO Issue Size | Website |
2011 | Pharmaceutical | ₹1513.60 Cr | http://www.glenmarklifesciences.com/ |
Our experts can help you prepare for SME IPO
The table below is live update of IPO bidding details from NSE and BSE.
Day | QIB | NII | RII | Total | |
---|---|---|---|---|---|
# of Shares Offered | 4,242,379 (28.25%) | 3,232,770 (21.53%) | 7,543,130 (50.23%) | 15,018,279 | |
1 | 27th Jul 2021 17:02 | 0.00x | 0.86x | 5.17x | 2.78x |
2 | 28th Jul 2021 17:03 | 1.38x | 3.39x | 9.28x | 5.78x |
3 | 29th Jul 2021 17:03 | 36.97x | 122.54x | 14.63x | 44.17x |
Glenmark Life Sciences Limited Financials | 31-Mar-2021 | 31-Mar-2020 | 31-Mar-2019 |
---|---|---|---|
Total Assets | ₹1,997.08 Cr | ₹1,725.60 Cr | ₹1,475.40 Cr |
Total Income | ₹1,885.98 Cr | ₹1,549.30 Cr | ₹886.87 Cr |
Net Profit/Loss | ₹351.58 Cr | ₹313.10 Cr | ₹195.59 Cr |
Last Updated on 27-Sep-2021 10:41:33